Concepedia

Ryo Dairiki

RD

Statistics

Publications

9

Citations

995

H-Index

9

Active since

2012

Affiliations

Takeda (Japan)(Current)

Medizinische Hochschule Hannover

Eisai (United States)

Eisai (Japan)

Centrum Onkologii

Ryo Dairiki is an author at Takeda (Japan) specializing in cancer pharmacology, oncology, and medicine.

Publications per year

2012–2021

9

Publications

9

Amplification-free whole-genome bisulfite sequencing by post-bisulfite adaptor tagging

Fumihito Miura, Yusuke Enomoto, Ryo Dairiki et al. · Nucleic Acids Research · 2012 · 451 citations · Full text

, , +14

Inhibitors of CLK Protein Kinases Suppress Cell Growth and Induce Apoptosis by Modulating Pre-mRNA Splicing

Shinsuke Araki, Ryo Dairiki, Yusuke Nakayama et al. · PLoS ONE · 2015 · 122 citations · Full text

, , +15

A Novel LSD1 Inhibitor T-3775440 Disrupts GFI1B-Containing Complex Leading to Transdifferentiation and Impaired Growth of AML Cells

Yoshinori Ishikawa, Kanae Gamo, Masato Yabuki et al. · Molecular Cancer Therapeutics · 2016 · 105 citations

, , +13

Anti‐tumor efficacy of a novel CLK inhibitor via targeting RNA splicing and MYC‐dependent vulnerability

Kenichi Iwai, Masahiro Yaguchi, Kazuho Nishimura et al. · EMBO Molecular Medicine · 2018 · 91 citations · Full text

, , +9

Pharmacodynamic Biomarkers Predictive of Survival Benefit with Lenvatinib in Unresectable Hepatocellular Carcinoma: From the Phase III REFLECT Study

Richard S. Finn, Masatoshi Kudo, Ann‐Lii Cheng et al. · Clinical Cancer Research · 2021 · 77 citations · Full text

, , +17

1–5 of 9